[1]
|
Siegel, R.L., Miller, K.D., Fuchs, H.E., et al. (2022) Cancer Statistics, 2022. CA: A Cancer Journal for Clinicians, 72, 7-33. https://doi.org/10.3322/caac.21708
|
[2]
|
Rudin, C.M., Poirier, J.T., Byers, L.A., et al. (2019) Molecular Subtypes of Small Cell Lung Cancer: A Synthesis of Human and Mouse Model Data. Nature Reviews Cancer, 19, 289‐297. https://doi.org/10.1038/s41568-019-0133-9
|
[3]
|
Drapkin, B.J. and Rudin, C.M. (2021) Advances in Small‐Cell Lung Cancer (SCLC) Translational Research. Cold Spring Harbor Perspectives in Medicine, 11, a038240. https://doi.org/10.1101/cshperspect.a038240
|
[4]
|
Bernhardt, E.B. and Jalal, S.I. (2016) Small Cell Lung Cancer. Cancer Treatment and Research, 170, 301-322. https://doi.org/10.1007/978-3-319-40389-2_14
|
[5]
|
Waqar, S.N. and Morgensztern, D. (2017) Treatment Advances in Small Cell Lung Cancer (SCLC). Pharmacology & Therapeutics, 180, 16-23. https://doi.org/10.1016/j.pharmthera.2017.06.002
|
[6]
|
Stinchcombe, T.E. (2017) Current Treatments for Surgically Resectable, Limited-Stage, and Extensive-Stage Small Cell Lung Cancer. Oncologist, 22, 1510-1517. https://doi.org/10.1634/theoncologist.2017-0204
|
[7]
|
Lara, P.N., Natale, R., Crowley, J., Lenz, H.J., Redman, M.W., Carleton, J.E., et al. (2009) Phase III Trial of Irinotecan/Cisplatin Compared with Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results from SWOG S0124. Journal of Clinical Oncology, 27, 2530-2535. https://doi.org/10.1200/JCO.2008.20.1061
|
[8]
|
Rossi, A., Di Maio, M., Chiodini, P., Rudd, R.M., Okamoto, H., Skarlos, D.V., et al. (2012) Carboplatin-or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data. Journal of Clinical Oncology, 30, 1692-1698. https://doi.org/10.1200/JCO.2011.40.4905
|
[9]
|
Ito, T., Kudoh, S., Ichimura, T., Fujino, K., Hassan, W.A. and Udaka, N. (2017) Small Cell Lung Cancer, an Epithelial to Mesenchymal Transition (EMT)-Like Cancer: Significance of Inactive Notch Signaling and Expression of Achaete-Scute Complex Homologue 1. Human Cell, 30, 1-10. https://doi.org/10.1007/s13577-016-0149-3
|
[10]
|
Gazdar Adi, F., Bunn Paul, A. and Minna John, D. (2017) Small-Cell Lung Cancer: What We Know, What We Need to Know and the Path Forward. Nature Reviews Cancer, 17, Article No. 765. https://doi.org/10.1038/nrc.2017.106
|
[11]
|
Horn, L., Mansfield, A.S., Szczęsna, A., et al. (2018) First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. The New England Journal of Medicine, 379, 2220-2229. https://doi.org/10.1056/NEJMoa1809064
|
[12]
|
George, J., Lim, J.S., Jang, S.J., et al. (2015) Comprehensive Genomic Profiles of Small Cell Lung Cancer. Nature, 524, 47‐53. https://doi.org/10.1038/nature14664
|
[13]
|
Harbour, J.W., Lai, S.L., Whang‐Peng, J., Gazdar, A.F., Minna, J.D. and Kaye, F.J. (1988) Abnormalities in Structure and Expression of the Human Retino-Blastoma Gene in SCLC. Science, 241, 353‐357. https://doi.org/10.1126/science.2838909
|
[14]
|
Takahashi, T., Nau, M.M., Chiba, I., et al. (1989) P53: A Frequent Target Forgenetic Abnormalities in Lung Cancer. Science, 246, 491‐494. https://doi.org/10.1126/science.2554494
|
[15]
|
Sutherland, K.D., Proost, N., Brouns, I., Adriaensen, D., Song, J.Y. and Berns, A. (2011) Cell of Origin of Small Cell Lung Cancer: Inactivation of Trp53 AndRb1 in Distinct Cell Types of Adult Mouse Lung. Cancer Cell, 19, 754‐764. https://doi.org/10.1016/j.ccr.2011.04.019
|
[16]
|
Huang, Y.H., Klingbeil, O., He, X.Y., et al. (2018) POU2F3 Is a Master Regulator of a Tuft Cell‐Like Variant of Small Cell Lung Cancer. Genes & Development, 32, 915‐928. https://doi.org/10.1101/gad.314815.118
|
[17]
|
Chen, H.J., Poran, A., Unni, A.M., et al. (2019) Generation of Pulmonary Neuro-Endocrine Cells and SCLC‐Like Tumors from Human Embryonic Stem Cells. Journal of Experimental Medicine, 216, 674‐687. https://doi.org/10.1084/jem.20181155
|
[18]
|
Pardoll, D.M. (2012) The Blockade of Immune Checkpoints in Cancer Immunotherapy. Nature Reviews Cancer, 12, 252-264. https://doi.org/10.1038/nrc3239
|
[19]
|
De Sousa Linhares, A., Battin, C., Jutz, S., et al. (2019) Therapeutic PD-L1 Antibodies Are More Effective than PD-1 Antibodies in Blocking PD-1/PD-L1 Signaling. Scientific Reports, 9, Article No. 11472. https://doi.org/10.1038/s41598-019-47910-1
|
[20]
|
Kwok, G., Yau, T.C., Chiu, J.W., Tse, E. and Kwong, Y.L. (2016) Pembrolizumab (Keytruda). Human Vaccines & Immunotherapeutics, 12, 2777-2789. https://doi.org/10.1080/21645515.2016.1199310
|
[21]
|
Chung, H.C., Lopez-Martin, J.A., Kao, S.C.H., Miller, W.H., Ros, W. and Gao, B. (2018) Phase 2 Study of Pembrolizumab in Advanced Small-Cell Lung Cancer (SCLC): KEYNOTE-158. Journal of Clinical Oncology, 15, 8506. https://doi.org/10.1200/JCO.2018.36.15_suppl.8506
|
[22]
|
Chung, H.C., Piha-Paul, S.A., Lopez-Martin, J., Schellens, J.H.M., Kao, S., Miller Jr., W.H., et al. (2019) Pembrolizumab after Two or More Lines of Priortherapy in Patients with Advanced Small-Cell Lung Cancer (SCLC): Results from the KEYNOTE-028 and KEYNOTE-158 Studies. Cancer Research, 79, CT073. https://doi.org/10.1158/1538-7445.AM2019-CT073
|
[23]
|
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., et al. (2015) Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 373, 1627-1639. https://doi.org/10.1056/NEJMoa1507643
|
[24]
|
Brahmer, J., Reckamp, K.L., Baas, P., Crino, L., Eberhardt, W.E., Poddubskaya, E., et al. (2015) Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 373, 123-135. https://doi.org/10.1056/NEJMoa1504627
|
[25]
|
Yang, S., Zhang, Z. and Wang, Q. (2019) Emerging Therapies for Small Cell Lung Cancer. Journal of Hematology & Oncology, 12, Article No. 47. https://doi.org/10.1186/s13045-019-0736-3
|
[26]
|
Cho, D.C., Mahipal, A., Dowlati, A., Chow, W.A., Segal, N.H., Chung, K.Y., et al. (2018) Safety and Clinical Activity of Durvalumab in Combination with Tremelimumab in Extensive Disease Small-Cell Lung Cancer (ED-SCLC). Journal of Clinical Oncology, 36, 8517. https://doi.org/10.1200/JCO.2018.36.15_suppl.8517
|
[27]
|
Walunas, T.L., Lenschow, D.J., Bakker, C.Y., Linsley, P.S., Freeman, G.J., Green, J.M., et al. (1994) Ctla-4 Can Function as a Negative Regulator of T-Cell Activation. Immunity, 1, 405-413. https://doi.org/10.1016/1074-7613(94)90071-X
|
[28]
|
Page, D.B., Yuan, J. and Wolchok, J.D. (2010) Targeting Cytotoxic T-Lymphocyte Antigen 4 in Immunotherapies for Melanoma and Other Cancers. Immunotherapy, 2, 367-379. https://doi.org/10.2217/imt.10.21
|
[29]
|
Small, E.J., Tchekmedyian, N.S., Rini, B.I., Fong, L., Lowy, I. and Allison, J.P. (2007) A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer. Clinical Cancer Research, 13, 1810-1815. https://doi.org/10.1158/1078-0432.CCR-06-2318
|
[30]
|
Hodi, F.S., Butler, M., Oble, D.A., Seiden, M.V., Haluska, F.G., Kruse, A., et al. (2008) Immunologic and Clinical Effects of Antibody Blockade of Cytotoxic Tlymphocyte-Associated Antigen 4 in Previously Vaccinated Cancer Patients. Proceedings of the National Academy of Sciences of the United States of America, 105, 3005-3010. https://doi.org/10.1073/pnas.0712237105
|
[31]
|
Ott, P.A., Elez, E., Hiret, S., Kim, D.W., Morosky, A., Saraf, S., et al. (2017) Pembrolizumab in Patients with Extensive-Stage Small-Cell Lung Cancer: Results from the Phase Ib KEYNOTE-028 Study. Journal of Clinical Oncology, 35, 3823-3829. https://doi.org/10.1200/JCO.2017.72.5069
|
[32]
|
Simpson-Abelson, M.R., D’Arigo, K., Hilton, F., et al. (2020) 1053P Iovance Generation-2 Tumour-Infiltrating Lymphocyte (TIL) Product Is Reinvigorated during the Manufacturing Process. Annals of Oncology, 31, S720. https://doi.org/10.1016/j.annonc.2020.08.1173
|
[33]
|
Owens, G.L., Price, M.J., Cheadle, E.J., et al. (2018) Ex Vivo Expanded TumourInfiltrating Lymphocytes from Ovarian Cancer Patients Release AntiTumour Cytokines in Response to Autologous Primary Ovarian Cancer Cells. Cancer Immunology, Immunotherapy, 67, 1519-1531. https://doi.org/10.1007/s00262-018-2211-3
|
[34]
|
Wang, S., Sun, J., Chen, K., et al. (2021) Perspectives of Tumor-Infiltrating Lymphocyte Treatment in Solid Tumors. BMC Medicine, 19, Article No. 140. https://doi.org/10.1186/s12916-021-02006-4
|
[35]
|
Rosenberg, S.A., Packard, B.S., Aebersold, P.M., et al. (1988) Use of TumorInfiltrating Lymphocytes and Interleukin2 in the Immunotherapy of Patients with Metastatic Melanoma. The New England Journal of Medicine, 319, 1676-1680. https://doi.org/10.1056/NEJM198812223192527
|
[36]
|
Topalian, S.L., Solomon, D., Avis, F.P., et al. (1988) Immunotherapy of Patients with Advanced Cancer Using Tumor-Infiltrating Lymphocytes and Recombinant Interleukin2: A Pilot Study. Journal of Clinical Oncology, 6, 839-853. https://doi.org/10.1200/JCO.1988.6.5.839
|
[37]
|
Dudley, M.E., Wunderlich, J.R., Yang, J.C., et al. (2005) Adoptive Cell Transfer Therapy Following NonMyeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients with Refractory Metastatic Melanoma. Journal of Clinical Oncology, 23, 2346-2357. https://doi.org/10.1200/JCO.2005.00.240
|
[38]
|
Rosenberg, S.A., Yannelli, J.R., Yang, J.C., et al. (1994) Treatment of Patients with Metastatic Melanoma with Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2. JNCI: Journal of the National Cancer Institute, 86, 1159-1166. https://doi.org/10.1093/jnci/86.15.1159
|
[39]
|
Rohaan, M.W., Borch, T.H., Van Den Berg, J.H., et al. (2022) TumorInfiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. The New England Journal of Medicine, 387, 2113-2125. https://doi.org/10.1056/NEJMoa2210233
|
[40]
|
Schoenfeld, A., Lee, S., Paz-Ares, L., et al. (2021) 458 First Phase 2 Results of Autologous TumorInfiltrating Lymphocyte (TIL; LN145) Monotherapyin Patients with Advanced, Immune Checkpoint InhibitorTreated, NonSmall Cell Lung Cancer (NSCLC). Journal for ImmunoTherapy of Cancer, 9, A486-A487. https://doi.org/10.1136/jitc-2021-SITC2021.458
|
[41]
|
Creelan, B.C., Wang, C., Teer, J.K., et al. (2021) Tumor-Infiltrating Lymphocyte Treatment for AntiPD-1-Resistant Metastatic Lung Cancer: A Phase 1 Trial. Nature Medicine, 27, 1410-1418. https://doi.org/10.1038/s41591-021-01462-y
|
[42]
|
Jazaeri, A.A., Zsiros, E., Amaria, R.N., et al. (2019) Safety and Efficacy of Adoptive Cell Transfer Using Autologous Tumor Infiltrating Lymphocytes (LN-145) for Treatment of Recurrent, Metastatic, or Persistent Cervical Carcinoma. Journal of Clinical Oncology, 37, 2538. https://doi.org/10.1200/JCO.2019.37.15_suppl.2538
|
[43]
|
O’Malley, D., Lee, S.M., Psyrri, A., et al. (2021) Phase 2 Efficacy and Safety of Autologous TumorInfiltrating Lymphocyte (TIL) Cell Therapy in Combination with Pembrolizumab in Immune Checkpoint InhibitorNaïve Patients with Advanced Cancers. Journal for ImmunoTherapy of Cancer, 9, A523-A524.
|
[44]
|
Jimeno, A., Papa, S., Haigentz, M., et al. (2020) 353 Safety and Efficacy of Tumor Infiltrating Lymphocytes (TIL, LN-145) in Combination with Pembrolizumab for Advanced, Recurrent or Metastatic HNSCC. Journal for ImmunoTherapy of Cancer, 8, A215-A216. https://doi.org/10.1136/jitc-2020-SITC2020.0353
|
[45]
|
Zacharakis, N., Chinnasamy, H., Black, M., et al. (2018) Immune Recognition of Somatic Mutations Leading to Complete Durable Regression in Metastatic Breast Cancer. Nature Medicine, 24, 724-730. https://doi.org/10.1038/s41591-018-0040-8
|